The deregulation of energetic and cellular metabolism is a signature of cancer cells. Thus,
drugs targeting cancer cell metabolism may have promising therapeutic potential. Previous …

In light of a global rise in the number of patients with type 2 diabetes mellitus (T2DM) and
obesity, non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction …

Metformin, a biguanide antidiabetic, has been studied for its repurposing effects in oncology.
Although a modest effect was observed in a single-agent regimen, metformin can synergize …

Background Metabolic disorders are associated with increased incidence, aggressive
phenotype and poor outcome of breast cancer (BC) patients. For instance, hyperinsulinemia …

Background The clinical observation showed a potential additive effect of anti-PD-1 agents
and cetirizine in patients with advanced melanoma. Methods Clinical outcomes of …

Transarterial chemoembolization (TACE) is often used as a locoregional therapy for early
hepatocellular carcinoma (HCC) when local ablation or resection are not feasible, but …

There is an urgent need for exploring new actionable targets other than androgen receptor
to improve outcome from lethal castration-resistant prostate cancer. Tumor metabolism has …

Metformin has been under basic and clinical study as an oncological repurposing
pharmacological agent for several years, stemming from observational studies which …

Metformin has been used for the treatment of type II diabetes mellitus for decades due to its
safety, low cost, and outstanding hypoglycemic effect clinically. The mechanisms underlying …

Cellular death evasion is a defining characteristic of human malignancies and a significant
contributor to therapeutic inefficacy. As a result of oncogenic inhibition of cell death …